Hansa Biopharma Investor Presentation 2022

Hansa Biopharma presented its investor update at Aktiedagen Lund in September 2022, highlighting the European approval of Idefirix for kidney transplantation and a diversified clinical pipeline in transplantation and autoimmunity. The company reported 145 employees, ~$300M market cap, and sufficient cash funding through 2024, demonstrating strong momentum with a validated technology platform and growing international shareholder base.